Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Gen Fam Med ; 18(6): 436-438, 2017 12.
Article in English | MEDLINE | ID: mdl-29264081

ABSTRACT

An 82-year-old woman with primary biliary cholangitis was diagnosed with an irreversible neurological disorder, caused by metronidazole (MNZ)-induced encephalopathy. Although the disorder is a reversible pathological condition, in rare cases, it can cause serious sequelae or could even be fatal. Therefore, medications should be administered carefully, particularly in patients who require long-term administration of large doses or those with liver dysfunction.

2.
Kansenshogaku Zasshi ; 88(6 Suppl 11): 7-10, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25796920

ABSTRACT

We report the case of a 63-year-old man who presented at our hospital after experiencing fever and dyspnea for more than 1 month. Because his general condition was deteriorating, he was referred to our intensive care unit. He needed critical care and was treated with vasopressors, artificial ventilation, and continuous hemodialysis. Considering his systemic condition, hematological malignancy was suspected. Bone marrow and skin biopsies were performed, and the condition was diagnosed as diffuse large B-cell lymphoma. On the 15th day, suspecting infectious lung disease, we performed bronchoscopy, which showed Rhizopus infection. Thus, the patient was administered high- dose liposomal amphotericin B (10 mg/kg) therapy. On the 54th day, he died of a massive pulmonary hemorrhage. Autopsy revealed mucormycosis infection in multiple organs, including the lungs and liver. Vigilance regarding possible mucormycosis infection is required, even after initial chemotherapy in patients whose bone marrow is significantly affected by lymphoma cells and leukemic changes.

3.
J Infect Chemother ; 18(3): 395-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21989517

ABSTRACT

We report the case of a 63-year-old man who presented at our hospital after experiencing fever and dyspnea for more than 1 month. Because his general condition was deteriorating, he was referred to our intensive care unit. He needed critical care and was treated with vasopressors, artificial ventilation, and continuous hemodialysis. Considering his systemic condition, hematological malignancy was suspected. Bone marrow and skin biopsies were performed, and the condition was diagnosed as diffuse large B-cell lymphoma. On the 15th day, suspecting infectious lung disease, we performed bronchoscopy, which showed Rhizopus infection. Thus, the patient was administered high-dose liposomal amphotericin B (10 mg/kg) therapy. On the 54th day, he died of a massive pulmonary hemorrhage. Autopsy revealed mucormycosis infection in multiple organs, including the lungs and liver. Vigilance regarding possible mucormycosis infection is required, even after initial chemotherapy in patients whose bone marrow is significantly affected by lymphoma cells and leukemic changes.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/microbiology , Mucormycosis/etiology , Rhizopus/isolation & purification , Fatal Outcome , Humans , Male , Middle Aged , Mucormycosis/chemically induced , Mucormycosis/microbiology
4.
J Gastroenterol Hepatol ; 27(5): 888-92, 2012 May.
Article in English | MEDLINE | ID: mdl-22098133

ABSTRACT

BACKGROUND AND AIM: Helicobacter pylori eradication clearly decreases peptic ulcer recurrence rates. H. pylori eradication is achieved in 70-90% of cases, but treatment failures due to poor patient compliance and resistant organisms do occur. Lactobacillus gasseri can suppress both clarithromycin-susceptible and -resistant strains of H. pylori in vitro. The aim of this study was to determine the effect of pretreatment with L. gasseri- containing yogurt on H. pylori eradication. We conducted a randomized, controlled clinical trial in patients with H. pylori infection. METHODS: A total of 229 patients were randomized into either a 1-week triple therapy of rabeprazole (10 mg bid), amoxicillin (750 mg bid), and clarithromycin (200 mg bid) or triple therapy plus L. gasseri-containing yogurt. In the yogurt-plus-triple therapy groups, yogurt containing L. gasseri OLL2716 (112 g) was given twice daily for 4 weeks (3 weeks pretreatment and also 1 week during eradication therapy). Clarithromycin resistance was determined by the detection of a mutation in 23S rRNA using nested polymerase chain reaction and the direct sequencing of DNA from pretreatment feces. H. pylori eradication was diagnosed based on the urea breath test and a stool antigen test after 8 weeks of eradication. RESULTS: The status of H. pylori susceptibility to clarithromycin was successively determined in 188 out of 229 samples. The rate of infection with clarithromycin-resistant strains of H. pylori was 27.1%. Overall eradication (intention to treat/per protocol) was 69.3/74.5% for the triple-only group, and 82.6/85.6% for the yogurt-plus-triple group (P = 0.018/P = 0.041). Eradication of primary clarithromycin-resistant strains tended to be higher for yogurt-plus-triple therapy than triple-only therapy (38.5 vs 28.0%, respectively, P = 0.458). CONCLUSION: This study confirmed that the major cause of treatment failure is resistance to clarithromycin. A 4-week treatment with L. gasseri-containing yogurt improves the efficacy of triple therapy in patients with H. pylori infection.


Subject(s)
Antibiosis , Clarithromycin/therapeutic use , Drug Resistance, Bacterial , Helicobacter Infections/therapy , Helicobacter pylori , Lactobacillus , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Breath Tests , Combined Modality Therapy , Feces/microbiology , Female , Helicobacter pylori/genetics , Helicobacter pylori/immunology , Humans , Intention to Treat Analysis , Male , Middle Aged , Rabeprazole , Yogurt
6.
Intern Med ; 49(3): 209-13, 2010.
Article in English | MEDLINE | ID: mdl-20118596

ABSTRACT

An 81-year-old woman presented with a chief complaint of swelling of both lower legs. She had a history of surgery for cancers of the stomach, rectum and colon. Among her immediate family members, her son had colon and rectal cancers, and her sister had ovarian cancer. After close examination the patient was diagnosed with small intestine cancer and ascending colon cancer. Gene mutation analyses did not reveal any mutations in DNA mismatch repair genes, but MSH-2 protein expression was lost only in the cancer lesions. Here, we report this rare case of eight metachronous gastrointestinal cancers thought to be HNPCC.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis , MutS Homolog 2 Protein/analysis , Neoplasms, Second Primary/diagnosis , Aged, 80 and over , Female , Humans , Immunohistochemistry
7.
Tokai J Exp Clin Med ; 35(1): 21-4, 2010 Apr 20.
Article in English | MEDLINE | ID: mdl-21319021

ABSTRACT

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a rare complication of adult Still's disease (ASD). We experienced a male ASD patient who complained of arthralgia and intermittent fever. Chest radiograph and pleural fluid analysis revealed pleurisy with effusion. We diagnosed this patient with SIADH and confirmed the disappearance of hyponatremia and pleurisy after starting treatment with nonsteroidal anti-inflammatory drugs. In this study, we reviewed previous literature and the case of our ASD patient with hyponatremia. This reported case is the fourth case of SIADH in an ASD patient. Further, we found that hyponatremia is a relatively common complication of ASD, and pleurisy has a possibility to develop SIADH in patients with ASD.


Subject(s)
Inappropriate ADH Syndrome/etiology , Still's Disease, Adult-Onset/complications , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Humans , Hyponatremia/etiology , Inappropriate ADH Syndrome/complications , Inappropriate ADH Syndrome/drug therapy , Lung/diagnostic imaging , Lung/pathology , Male , Middle Aged , Pleurisy/etiology , Radiography
8.
Tokai J Exp Clin Med ; 35(4): 126-9, 2010 Dec 20.
Article in English | MEDLINE | ID: mdl-21319041

ABSTRACT

Granulicatella adiacens is a nutritionally variant streptococci. Only 3 cases of vertebral osteomyelitis due to these microorganisms have been reported. We experienced a 73-year-old male who consulted us due to fever and back pain of about 1-month duration. On examination, a presystolic murmur was heard in the apical region. Echocardiography showed prolapse of the mitral valve, but no vegetation was observed. MRI revealed osteomyelitis of lumbar vertebrae. As G. adiacens was detected in blood culture, it was determined as the cause of vertebral osteomyelitis, and combination antibiotics therapy was started. The condition improved, the patient underwent valvoplasty, and no trace of infective endocarditis was noted in the resected valve. All the previous cases had infection caused by G. adiacens and complicated with infective endocarditis. This is the first case without infective endocarditis. Vertebral osteomyelitis due to NVS is very rare. Since nutritionally variant streptococci do not grow in common culture media, and since the sensitivity of isolation by standard conventional biochemical methods is low, the condition may be misdiagnosed as blood-culture-negative vertebral osteomyelitis. Therefore, the possibility of nutritionally variant streptococci infection should be considered if a patient with vertebral osteomyelitis shows a positive Gram stain but negative blood cultures.


Subject(s)
Bacterial Infections/microbiology , Bacterial Infections/pathology , Carnobacteriaceae/pathogenicity , Lumbar Vertebrae/microbiology , Lumbar Vertebrae/pathology , Osteomyelitis/microbiology , Osteomyelitis/pathology , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Endocarditis , Humans , Male , Mitral Valve/surgery , Osteomyelitis/diagnosis , Osteomyelitis/drug therapy
9.
J Gastroenterol ; 44(7): 713-6, 2009.
Article in English | MEDLINE | ID: mdl-19458898

ABSTRACT

BACKGROUND: Recently, a novel Helicobacter pylori stool antigen test (Testmate pylori antigen EIA) using monoclonal antibodies against H. pylori catalase has been developed commercially. This study assessed the diagnostic usefulness of the stool antigen test compared with a polyclonal enzyme immunoassay (HpSA test) after H. pylori eradication. METHODS: A total of 150 patients with H. pylori infection were treated by triple therapy with PPI and amoxicillin with either clarithromycin or metronidazole. H. pylori stool antigen was tested 4 and 8 weeks after eradication. The outcome of H. pylori eradication was assessed by urea breath test (UBT) 8 weeks after the end of therapy. Discordant results were followed by endoscopic examination. RESULTS: Of 150 patients enrolled, H. pylori status was negative in 122 cases and positive in 28 cases, assessed by the 13C-UBT. On the other hand, the monoclonal stool antigen test results were negative in 126 cases and positive in 24. The polyclonal stool test results were negative in 126 cases and positive in 22. The overall sensitivity and specificity of the monoclonal stool antigen test were 91.6% (95% CI 85.9-97.3%) and 98.4% (95% CI 97.3-99.5%). The overall sensitivity and specificity of the polyclonal stool antigen test were 87.0% (95% CI 86.9-94.0%) and 97.5% (95% CI 96.1-98.9%). CONCLUSION: The new stool antigen test using monoclonal antibody is useful for the diagnosis of H. pylori eradication 4 weeks after the end of treatment.


Subject(s)
Antibodies, Bacterial , Antibodies, Monoclonal , Antigens, Bacterial/analysis , Feces/microbiology , Helicobacter Infections/drug therapy , Helicobacter pylori/immunology , Immunoenzyme Techniques/methods , Adolescent , Adult , Amoxicillin/administration & dosage , Anti-Bacterial Agents/therapeutic use , Clarithromycin/administration & dosage , Female , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Humans , Male , Metronidazole/administration & dosage , Middle Aged , Proton Pump Inhibitors/administration & dosage , Sensitivity and Specificity
10.
Tokai J Exp Clin Med ; 30(2): 133-6, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16146205

ABSTRACT

Lung involvement is rare in Waldenström macroglobulinemia (WM). We encountered a male patient with WM who complained of breathlessness. Chest X-ray revealed diffuse infiltrative shadow throughout the both lungs. Transbronchial biopsy showed infiltration of atypical plasmacytoid lymphocytes and non-caseating granuloma. We treated the patients with fludarabine phosphate, and both his symptom and X-ray findings were then improved. To our knowledge, this is the first case showing non-caseating granuloma with lung involvement of WM. We discuss a mechanism of non-caseating granuloma formation in this case.


Subject(s)
Plasma Cell Granuloma, Pulmonary/etiology , Waldenstrom Macroglobulinemia/complications , Antimetabolites, Antineoplastic/therapeutic use , Humans , Male , Middle Aged , Plasma Cell Granuloma, Pulmonary/diagnostic imaging , Plasma Cell Granuloma, Pulmonary/drug therapy , Radiography , Treatment Outcome , Vidarabine Phosphate/analogs & derivatives , Vidarabine Phosphate/therapeutic use , Waldenstrom Macroglobulinemia/diagnostic imaging , Waldenstrom Macroglobulinemia/drug therapy
11.
J Gastroenterol ; 40(8): 796-801, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16143884

ABSTRACT

BACKGROUND: Interkeukin-1 (IL-1) gene cluster polymorphisms that are thought to enhance the production of IL-1beta are associated with an increased risk of gastric cancer. To determine the role of host genetic factors in Helicobacter pylori infection, we examined the relationship between gastric mucosal IL-1beta levels and IL-1B polymorphisms in patients with H. pylori infection. METHODS: Biopsy tissues obtained from 99 patients were homogenized and gastric mucosal IL-1beta levels were measured by enzyme-linked immunosorbent assay (ELISA). Single-base polymorphisms at positions -511 and -31 in IL-1B were analyzed. RESULTS: The IL-1beta level in the antrum was significantly higher in genotype IL-1B-511C/C than in H. pylori-negative patients (P < 0.05). The IL-1B polymorphism did not influence the degree of gastric neutrophil and mononuclear cell infiltration, or gastric atrophy. IL-1beta levels in the corpus, but not those in the antrum, correlated to the severity of gastric atrophy. CONCLUSIONS: These findings indicate that IL-1B polymorphisms enhance IL-1beta production in the antrum; however, other factors might regulate the production of IL-1beta in the corpus of the stomach, regardless of IL-1B polymorphisms, and high IL-1beta production may be associated with the grade of gastric atrophy in the corpus mucosa in patients with H. pylori infection.


Subject(s)
Gastric Mucosa/chemistry , Helicobacter Infections/genetics , Helicobacter Infections/metabolism , Helicobacter pylori , Interleukin-1/analysis , Interleukin-1/genetics , Polymorphism, Genetic , Adult , Aged , Aged, 80 and over , Atrophy , Biopsy , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-1/biosynthesis , Male , Middle Aged , Pyloric Antrum/pathology
12.
Rinsho Ketsueki ; 45(12): 1255-7, 2004 Dec.
Article in Japanese | MEDLINE | ID: mdl-15678918

ABSTRACT

We measured rituximab concentrations in the cerebrospinal fluid (CSF) in 2 patients with diffuse large B-cell lymphoma in whom central nervous system (CNS) invasion had developed. They received rituximab intravenously following irradiation therapy (patient no.1) or along with chemotherapy (patient no.2). The rituximab concentrations in the CSF were considered to be very low (0.2-0.6 microg/ml), and could not be increased significantly by serial intravenous administrations of rituximab. The lymphoma relapsed in patient no.1, and the combined therapy was not effective in patient no.2. An alternative approach such as intrathecal administration of rituximab could be anticipated as a new therapeutic strategy for CNS lymphoma.


Subject(s)
Antibodies, Monoclonal/cerebrospinal fluid , Antineoplastic Agents/cerebrospinal fluid , Brain Neoplasms/drug therapy , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Aged , Antibodies, Monoclonal, Murine-Derived , Brain Neoplasms/cerebrospinal fluid , Female , Humans , Lymphoma, B-Cell/cerebrospinal fluid , Lymphoma, Large B-Cell, Diffuse/cerebrospinal fluid , Rituximab
SELECTION OF CITATIONS
SEARCH DETAIL
...